Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies

被引：0
|
作者：
Arnold, Douglas
Cohen, Jeffrey
Barkhof, Frederik
Selmaj, Krzysztof
Margolin, David
Palmer, Jeffrey
Fox, Edward
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E35 / E36
页数：2
相关论文
共 50 条
  • [21] Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study
    Soelberg-Sorensen, Per
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Twyman, Cary
    Lake, Stephen
    Margolin, David
    Richards, Susan
    Sung, Crystal
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [22] Alemtuzumab has a durable effect on disability improvement in treatment-naive patients with relapsing-remitting multiple sclerosis: a 4-year follow-up of CARE-MS I
    Fernandez Fernandez, O.
    Hartung, H-P
    LaGanke, C.
    Margolin, D. H.
    Kasten, L.
    Moreau, T.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 824 - 824
  • [23] Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II
    Fernandez, O.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Twyman, C. L.
    Miller, T.
    Lake, L.
    Margolin, D. H.
    Panzara, M. A.
    JOURNAL OF NEUROLOGY, 2013, 260 : S14 - S14
  • [24] Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study
    Coles, A. J.
    Arnold, D. L.
    Cohen, J. A.
    Fox, E. J.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 107 - 108
  • [25] Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study
    Macdonell, R. A. L.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 806 - 806
  • [26] Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up
    Boyko, Alexey N.
    Barnett, Michael
    Brassat, David
    Dive, Dominique
    Hupperts, Raymond M. M.
    Lycke, Jan
    Montalban, Xavier
    Sharrack, Basil
    Wray, Sibyl
    Margolin, David H.
    Thangavelu, Karthinathan
    Chirieac, Madalina
    Wiendl, Heinz
    NEUROLOGY, 2017, 88
  • [27] Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 235 - 235
  • [28] Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study
    Hartung, H-P
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 85 - 86
  • [29] Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study
    Vucic, S.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 821 - 821
  • [30] Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France
    Ayrignac, Xavier
    Collongues, Nicolas
    De Seze, Jerome
    Vermersch, Patrick
    Biotti, Damien
    Brassat, David
    Vukusic, Sandra
    Durand-Dubief, Francoise
    Edan, Gilles
    Lepage, Emmanuelle
    Deburghgraeve, Veronique
    Maillart, Elisabeth
    Papeix, Caroline
    Alla, Philippe
    Berger, Eric
    Bourre, Bertrand
    Casez, Olivier
    Pittion, Sophie
    Debouverie, Marc
    Theaudin, Marie
    Derache, Nathalie
    Defer, Gilles
    Gout, Olivier
    Deschamps, Romain
    Tourbah, Ayman
    Zagnoli, Fabien
    Ruet, Aurelie
    Ouallet, Jean
    Brochet, Bruno
    Manchon, Eric
    Moreau, Thibault
    Fromont, Agnes
    Clavelou, Pierre
    Guennoc, Anne Marie
    Camdessanche, Jean-Phillippe
    Carpentier, Antoine
    Coman, Irene Antoanela
    Audoin, Bertrand
    Pelletier, Jean
    Magy, Laurent
    Ciron, Jonathan
    Wiertlevski, Sandrine
    Laplaud, David
    De Broucker, Thomas
    Frenay, Christine Lebrun
    Cohen, Mikael
    Labauge, Pierre
    NEUROLOGY, 2017, 88
12345